JP2016503295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503295A5 JP2016503295A5 JP2015540250A JP2015540250A JP2016503295A5 JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5 JP 2015540250 A JP2015540250 A JP 2015540250A JP 2015540250 A JP2015540250 A JP 2015540250A JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723545P | 2012-11-07 | 2012-11-07 | |
| US61/723,545 | 2012-11-07 | ||
| US201361749610P | 2013-01-07 | 2013-01-07 | |
| US61/749,610 | 2013-01-07 | ||
| US201361886156P | 2013-10-03 | 2013-10-03 | |
| US61/886,156 | 2013-10-03 | ||
| US201361889179P | 2013-10-10 | 2013-10-10 | |
| US61/889,179 | 2013-10-10 | ||
| PCT/IB2013/059786 WO2014072888A1 (en) | 2012-11-07 | 2013-10-30 | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503295A JP2016503295A (ja) | 2016-02-04 |
| JP2016503295A5 true JP2016503295A5 (enExample) | 2016-12-22 |
Family
ID=49955428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540250A Pending JP2016503295A (ja) | 2012-11-07 | 2013-10-30 | 抗ｉｌ−１３受容体アルファ２抗体および抗体−薬物コンジュゲート |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9828428B2 (enExample) |
| EP (1) | EP2916875A1 (enExample) |
| JP (1) | JP2016503295A (enExample) |
| KR (1) | KR101763499B1 (enExample) |
| CN (1) | CN104936621A (enExample) |
| AU (1) | AU2013343111A1 (enExample) |
| CA (1) | CA2890256A1 (enExample) |
| HK (1) | HK1214161A1 (enExample) |
| IL (1) | IL238566A0 (enExample) |
| MX (1) | MX2015005582A (enExample) |
| PE (1) | PE20150891A1 (enExample) |
| PH (1) | PH12015500977A1 (enExample) |
| RU (1) | RU2015116485A (enExample) |
| SG (1) | SG11201503431TA (enExample) |
| WO (1) | WO2014072888A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| SG10201804945WA (en) * | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015183978A1 (en) * | 2014-05-28 | 2015-12-03 | Agensys, Inc. | Derivatives of dolaproine-dolaisoleuine peptides |
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| EP4592311A3 (en) | 2015-02-16 | 2026-02-25 | Lonza Ltd | Antibodies |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| TWI727380B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| TWI812873B (zh) * | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| WO2017107817A1 (zh) * | 2015-12-21 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| CN108456250B (zh) | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN107880131A (zh) * | 2017-08-14 | 2018-04-06 | 四川大学 | 一种抗IL‑13Rα2和CD3双特异抗体及其应用 |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
| JP7337079B2 (ja) | 2018-02-15 | 2023-09-01 | マクロジェニクス，インコーポレーテッド | 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| EA202091984A1 (ru) | 2018-03-14 | 2021-02-18 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 |
| EP3765041A4 (en) * | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| US11478553B2 (en) | 2019-02-15 | 2022-10-25 | Wuxi Biologies Ireland Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| IL295434A (en) | 2020-02-21 | 2022-10-01 | Macrogenics Inc | cd137 binding molecules and their uses |
| US20230183364A1 (en) * | 2020-05-15 | 2023-06-15 | Elicera Therapeutics Ab | Anti-IL13R-alpha2 Antibodies, Antigen-Binding Fragments and Uses Thereof |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| CN117043192B (zh) * | 2021-02-19 | 2024-05-03 | 上海齐鲁制药研究中心有限公司 | 针对IL-13Rα2的抗体及其应用 |
| EP4365203A4 (en) | 2021-07-01 | 2025-09-24 | Ningbo T Maximum Biopharmaceuticals Co Ltd | ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION |
| WO2023274380A1 (zh) | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
| JP2025505777A (ja) * | 2022-02-17 | 2025-02-28 | ラノバ メディシンズ デベロップメント カンパニー， リミテッド | 抗ｉｌ－１３ｒａ２モノクローナル抗体およびその使用 |
| EP4577575A1 (en) * | 2022-08-25 | 2025-07-02 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| EP4596687A1 (en) * | 2022-09-30 | 2025-08-06 | The University of Tokyo | Il13ra2-targeting herpes simplex virus and anti-il13ra2 antibody or antigen-binding fragment thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| WO2002017968A2 (en) * | 2000-08-31 | 2002-03-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
| AU2007319605B2 (en) | 2006-10-19 | 2011-02-17 | Csl Limited | Anti-IL-13R alpha 1 antibodies and their uses thereof |
| PL2829551T3 (pl) | 2006-10-19 | 2018-04-30 | Csl Limited | Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13 |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| RU2012157167A (ru) | 2010-07-12 | 2014-08-20 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Полифункциональные антительные конъюгаты |
| CN104185477B (zh) * | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| EP3447071A1 (en) | 2012-01-09 | 2019-02-27 | Pfizer Healthcare Ireland | Mutant antibodies and conjugation thereof |
-
2013
- 2013-10-30 KR KR1020157011436A patent/KR101763499B1/ko not_active Expired - Fee Related
- 2013-10-30 AU AU2013343111A patent/AU2013343111A1/en not_active Abandoned
- 2013-10-30 CA CA2890256A patent/CA2890256A1/en not_active Abandoned
- 2013-10-30 RU RU2015116485A patent/RU2015116485A/ru not_active Application Discontinuation
- 2013-10-30 SG SG11201503431TA patent/SG11201503431TA/en unknown
- 2013-10-30 HK HK16102252.1A patent/HK1214161A1/zh unknown
- 2013-10-30 US US14/439,897 patent/US9828428B2/en active Active
- 2013-10-30 EP EP13820931.7A patent/EP2916875A1/en not_active Withdrawn
- 2013-10-30 PE PE2015000568A patent/PE20150891A1/es not_active Application Discontinuation
- 2013-10-30 WO PCT/IB2013/059786 patent/WO2014072888A1/en not_active Ceased
- 2013-10-30 MX MX2015005582A patent/MX2015005582A/es unknown
- 2013-10-30 JP JP2015540250A patent/JP2016503295A/ja active Pending
- 2013-10-30 CN CN201380057103.5A patent/CN104936621A/zh active Pending
-
2015
- 2015-04-30 IL IL238566A patent/IL238566A0/en unknown
- 2015-04-30 PH PH12015500977A patent/PH12015500977A1/en unknown